Abstract
AbstractOrgan decellularization creates cell-free, collagen-based extracellular matrices that can be used as scaffolds for tissue engineering applications. This technique has recently gained much attention, yet adequate scaffold repopulation and implantation remain a challenge. Specifically, there still needs to be a greater understanding of scaffold responses post-transplantation and ways we can improve scaffold durability to withstand the in vivo environment. Recent studies have outlined vascular events that limit organ decellularization/recellularization scaffold viability for long-term transplantation. However, these insights have relied on in vitro/in vivo approaches that need enhanced spatial and temporal resolutions to investigate such issues at the microvascular level. This study uses intravital microscopy to gain instant feedback on their structure, function, and deformation dynamics. Thus, the objective of this study was to capture the effects of in vivo blood flow on the decellularized glomerulus, peritubular capillaries, and tubules after autologous and allogeneic orthotopic transplantation into rats. Large molecular weight dextran molecules labeled the vasculature. They revealed substantial degrees of translocation from glomerular and peritubular capillary tracks to the decellularized tubular epithelium and lumen as early as 12 h after transplantation, providing real-time evidence of the increases in microvascular permeability. Macromolecular extravasation persisted for a week, during which the decellularized microarchitecture was significantly and comparably compromised and thrombosed in both autologous and allogeneic approaches. These results indicate that in vivo multiphoton microscopy is a powerful approach for studying scaffold viability and identifying ways to promote scaffold longevity and vasculogenesis in bioartificial organs.
Funder
Khalifa University of Science, Technology and Research
National Institutes of Health
Publisher
Springer Science and Business Media LLC
Reference81 articles.
1. Abecassis, M. et al. Kidney transplantation as primary therapy for end-stage renal disease: A National Kidney Foundation/kidney disease outcomes quality initiative (NKF/KDOQITM) conference. Clin. J. Am. Soc. Nephrol. 3(2), 471–480 (2008).
2. Ghahramani, N. et al. Nephrologists’ perceptions of renal transplant as treatment of choice for end-stage renal disease, preemptive transplant, and transplanting older patients: An international survey. Exp. Clin. Transplant. 9(4), 223–229 (2011).
3. Corridon, P. R. Still finding ways to augment the existing management of acute and chronic kidney diseases with targeted gene and cell therapies: Opportunities and hurdles. Front. Med. 10 (2023).
4. Corridon, P. R. et al. Bioartificial kidneys. Curr Stem Cell Rep 3(2), 68–76 (2017).
5. Kim, S. et al. Current strategies and challenges in engineering a bioartificial kidney. Front. Biosci. (Elite Ed.) 7, 215–228 (2015).
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献